{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,27]],"date-time":"2026-05-27T17:09:16Z","timestamp":1779901756831,"version":"3.53.1"},"reference-count":77,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2025,4,1]],"date-time":"2025-04-01T00:00:00Z","timestamp":1743465600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,4,1]],"date-time":"2025-04-01T00:00:00Z","timestamp":1743465600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2025,3,9]],"date-time":"2025-03-09T00:00:00Z","timestamp":1741478400000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/100016036","name":"Health~Holland","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100016036","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Vaccine"],"published-print":{"date-parts":[[2025,4]]},"DOI":"10.1016\/j.vaccine.2025.126989","type":"journal-article","created":{"date-parts":[[2025,3,13]],"date-time":"2025-03-13T21:23:28Z","timestamp":1741901008000},"page":"126989","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":4,"special_numbering":"C","title":["Targeting the early life stages of SARS-CoV-2 using a multi-peptide conjugate vaccine"],"prefix":"10.1016","volume":"54","author":[{"given":"Lauren","family":"Myburgh","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Haiko","family":"Karsjens","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Athanasios","family":"Blanas","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Aafke","family":"de Ligt","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Karlijn","family":"van Loon","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Elisabeth J.M.","family":"Huijbers","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Judy R.","family":"van Beijnum","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Diederik J.M.","family":"Engbersen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Abdessalem","family":"Rekiki","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Charlotte","family":"Mignon","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Oxana","family":"Vratskikh","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Arjan W.","family":"Griffioen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.vaccine.2025.126989_bb0005","article-title":"Longitudinal analysis shows durable and broad immune memory after SARS-CoV-2 infection with persisting antibody responses and memory B and T cells","volume":"2","author":"Cohen","year":"2021","journal-title":"Cell Rep Med"},{"key":"10.1016\/j.vaccine.2025.126989_bb0010","doi-asserted-by":"crossref","first-page":"2043","DOI":"10.1001\/jama.2021.19499","article-title":"Association between mRNA vaccination and COVID-19 hospitalization and disease severity","volume":"326","author":"Tenforde","year":"2021","journal-title":"JAMA"},{"key":"10.1016\/j.vaccine.2025.126989_bb0015","doi-asserted-by":"crossref","first-page":"698","DOI":"10.1056\/NEJMc2119236","article-title":"SARS-CoV-2 omicron variant neutralization in serum from vaccinated and convalescent persons","volume":"386","author":"Rossler","year":"2022","journal-title":"N Engl J Med"},{"key":"10.1016\/j.vaccine.2025.126989_bb0020","doi-asserted-by":"crossref","DOI":"10.3390\/pathogens9030231","article-title":"SARS-CoV-2 and coronavirus disease 2019: What we know so far","volume":"9","author":"Rabi","year":"2020","journal-title":"Pathogens"},{"key":"10.1016\/j.vaccine.2025.126989_bb0025","doi-asserted-by":"crossref","first-page":"271","DOI":"10.1016\/j.cell.2020.02.052","article-title":"SARS-CoV-2 cell entry depends on ACE2 and TMPRSS2 and is blocked by a clinically proven protease inhibitor","volume":"181","author":"Hoffmann","year":"2020","journal-title":"Cell"},{"key":"10.1016\/j.vaccine.2025.126989_bb0030","doi-asserted-by":"crossref","first-page":"215","DOI":"10.1038\/s41586-020-2180-5","article-title":"Structure of the SARS-CoV-2 spike receptor-binding domain bound to the ACE2 receptor","volume":"581","author":"Lan","year":"2020","journal-title":"Nature"},{"key":"10.1016\/j.vaccine.2025.126989_bb0035","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2021.647934","article-title":"A structural landscape of neutralizing antibodies against SARS-CoV-2 receptor binding domain","volume":"12","author":"Niu","year":"2021","journal-title":"Front Immunol"},{"key":"10.1016\/j.vaccine.2025.126989_bb0040","doi-asserted-by":"crossref","first-page":"925","DOI":"10.1038\/s41594-020-0479-4","article-title":"Controlling the SARS-CoV-2 spike glycoprotein conformation","volume":"27","author":"Henderson","year":"2020","journal-title":"Nat Struct Mol Biol"},{"key":"10.1016\/j.vaccine.2025.126989_bb0045","doi-asserted-by":"crossref","first-page":"765","DOI":"10.1038\/s41423-020-0374-2","article-title":"Fusion mechanism of 2019-nCoV and fusion inhibitors targeting HR1 domain in spike protein","volume":"17","author":"Xia","year":"2020","journal-title":"Cell Mol Immunol"},{"key":"10.1016\/j.vaccine.2025.126989_bb0050","doi-asserted-by":"crossref","first-page":"3054","DOI":"10.1016\/j.vaccine.2018.03.064","article-title":"An improved conjugate vaccine technology; induction of antibody responses to the tumor vasculature","volume":"36","author":"Huijbers","year":"2018","journal-title":"Vaccine"},{"key":"10.1016\/j.vaccine.2025.126989_bb0055","doi-asserted-by":"crossref","first-page":"2842","DOI":"10.1038\/s41467-022-30063-7","article-title":"Extracellular vimentin mimics VEGF and is a target for anti-angiogenic immunotherapy","volume":"13","author":"van Beijnum","year":"2022","journal-title":"Nat Commun"},{"key":"10.1016\/j.vaccine.2025.126989_bb0060","doi-asserted-by":"crossref","DOI":"10.1016\/j.isci.2022.104719","article-title":"Vaccination with a bacterial peptide conjugated to SARS-CoV-2 receptor-binding domain accelerates immunity and protects against COVID-19","volume":"25","author":"Blanas","year":"2022","journal-title":"iScience"},{"key":"10.1016\/j.vaccine.2025.126989_bb0065","doi-asserted-by":"crossref","first-page":"722","DOI":"10.1016\/j.cell.2020.06.035","article-title":"A universal Design of Betacoronavirus Vaccines against COVID-19, MERS, and SARS","volume":"182","author":"Dai","year":"2020","journal-title":"Cell"},{"key":"10.1016\/j.vaccine.2025.126989_bb0070","article-title":"Virus-Receptor Interactions of Glycosylated SARS-CoV-2 Spike and Human ACE2 Receptor","author":"Zhao","year":"2020","journal-title":"bioRxiv"},{"key":"10.1016\/j.vaccine.2025.126989_bb0075","doi-asserted-by":"crossref","first-page":"13205","DOI":"10.1021\/jacs.1c05435","article-title":"Fusion peptide of SARS-CoV-2 spike rearranges into a wedge inserted in Bilayered micelles","volume":"143","author":"Koppisetti","year":"2021","journal-title":"J Am Chem Soc"},{"key":"10.1016\/j.vaccine.2025.126989_bb0080","doi-asserted-by":"crossref","first-page":"828","DOI":"10.1016\/j.cell.2020.06.025","article-title":"Structures of human antibodies bound to SARS-CoV-2 spike reveal common epitopes and recurrent features of antibodies","volume":"182","author":"Barnes","year":"2020","journal-title":"Cell"},{"key":"10.1016\/j.vaccine.2025.126989_bb0085","doi-asserted-by":"crossref","first-page":"20120","DOI":"10.1038\/s41598-022-24730-4","article-title":"Human antibody recognition and neutralization mode on the NTD and RBD domains of SARS-CoV-2 spike protein","volume":"12","author":"Otsubo","year":"2022","journal-title":"Sci Rep"},{"key":"10.1016\/j.vaccine.2025.126989_bb0090","doi-asserted-by":"crossref","DOI":"10.3390\/pharmaceutics14040856","article-title":"Peptide-based vaccine against SARS-CoV-2: Peptide antigen discovery and screening of adjuvant systems","volume":"14","author":"Shalash","year":"2022","journal-title":"Pharmaceutics"},{"key":"10.1016\/j.vaccine.2025.126989_bb0095","doi-asserted-by":"crossref","first-page":"4053","DOI":"10.4049\/jimmunol.1401031","article-title":"Dissecting the contribution of IgG subclasses in restricting airway infection with legionella pneumophila","volume":"193","author":"Weber","year":"2014","journal-title":"J Immunol"},{"key":"10.1016\/j.vaccine.2025.126989_bb0100","doi-asserted-by":"crossref","first-page":"664","DOI":"10.1038\/s41586-021-04386-2","article-title":"Broadly neutralizing antibodies overcome SARS-CoV-2 omicron antigenic shift","volume":"602","author":"Cameroni","year":"2022","journal-title":"Nature"},{"key":"10.1016\/j.vaccine.2025.126989_bb0105","doi-asserted-by":"crossref","first-page":"74","DOI":"10.1038\/s41590-020-00808-x","article-title":"SARS-CoV-2-derived peptides define heterologous and COVID-19-induced T cell recognition","volume":"22","author":"Nelde","year":"2021","journal-title":"Nat Immunol"},{"key":"10.1016\/j.vaccine.2025.126989_bb0110","doi-asserted-by":"crossref","first-page":"8","DOI":"10.1038\/s41590-020-00838-5","article-title":"Deciphering the ins and outs of SARS-CoV-2-specific T cells","volume":"22","author":"Perez-Potti","year":"2021","journal-title":"Nat Immunol"},{"key":"10.1016\/j.vaccine.2025.126989_bb0115","doi-asserted-by":"crossref","first-page":"834","DOI":"10.1038\/s41586-020-2342-5","article-title":"Pathogenesis and transmission of SARS-CoV-2 in golden hamsters","volume":"583","author":"Sia","year":"2020","journal-title":"Nature"},{"key":"10.1016\/j.vaccine.2025.126989_bb0120","doi-asserted-by":"crossref","DOI":"10.1126\/sciadv.abe8065","article-title":"Immunogenicity of clinically relevant SARS-CoV-2 vaccines in nonhuman primates and humans","volume":"7","author":"Klasse","year":"2021","journal-title":"Sci Adv"},{"key":"10.1016\/j.vaccine.2025.126989_bb0125","doi-asserted-by":"crossref","first-page":"403","DOI":"10.1007\/s40265-024-02013-8","article-title":"Current Progress, challenges and prospects in the development of COVID-19 vaccines","volume":"84","author":"Zhu","year":"2024","journal-title":"Drugs"},{"key":"10.1016\/j.vaccine.2025.126989_bb0130","doi-asserted-by":"crossref","DOI":"10.1128\/Spectrum.00965-21","article-title":"High-resolution linear epitope mapping of the receptor binding domain of SARS-CoV-2 spike protein in COVID-19 mRNA vaccine recipients","volume":"9","author":"Nitahara","year":"2021","journal-title":"Microbiol Spectr"},{"key":"10.1016\/j.vaccine.2025.126989_bb0135","article-title":"Rapid generation of neutralizing antibody responses in COVID-19 patients","volume":"1","author":"Suthar","year":"2020","journal-title":"Cell Rep Med"},{"key":"10.1016\/j.vaccine.2025.126989_bb0140","doi-asserted-by":"crossref","first-page":"169","DOI":"10.1186\/s12916-021-02055-9","article-title":"Humoral immune responses during SARS-CoV-2 mRNA vaccine administration in seropositive and seronegative individuals","volume":"19","author":"Fraley","year":"2021","journal-title":"BMC Med"},{"key":"10.1016\/j.vaccine.2025.126989_bb0145","article-title":"Serological analysis reveals an imbalanced IgG subclass composition associated with COVID-19 disease severity","volume":"2","author":"Yates","year":"2021","journal-title":"Cell Rep Med"},{"key":"10.1016\/j.vaccine.2025.126989_bb0150","doi-asserted-by":"crossref","DOI":"10.1371\/journal.ppat.1009101","article-title":"RV144 HIV-1 vaccination impacts post-infection antibody responses","volume":"16","author":"Mdluli","year":"2020","journal-title":"PLoS Pathog"},{"key":"10.1016\/j.vaccine.2025.126989_bb0155","doi-asserted-by":"crossref","first-page":"1549","DOI":"10.1097\/QAD.0000000000002944","article-title":"Serum IgG1 and IgG4 could contribute to partial control of viral rebound in chronically HIV-1-infected patients","volume":"35","author":"Pastori","year":"2021","journal-title":"Aids"},{"key":"10.1016\/j.vaccine.2025.126989_bb0160","first-page":"693","article-title":"Comparison of immunoglobulin G subclass profiles induced by measles virus in vaccinated and naturally infected individuals","volume":"9","author":"Isa","year":"2002","journal-title":"Clin Diagn Lab Immunol"},{"key":"10.1016\/j.vaccine.2025.126989_bb0165","doi-asserted-by":"crossref","first-page":"5935","DOI":"10.1038\/s41598-022-10020-6","article-title":"SARS-CoV-2 spike S1-specific IgG kinetic profiles following mRNA or vector-based vaccination in the general Dutch population show distinct kinetics","volume":"12","author":"van den Hoogen","year":"2022","journal-title":"Sci Rep"},{"key":"10.1016\/j.vaccine.2025.126989_bb0170","doi-asserted-by":"crossref","first-page":"265","DOI":"10.1111\/j.1600-065X.2010.00910.x","article-title":"Antibody-mediated modulation of immune responses","volume":"236","author":"Nimmerjahn","year":"2010","journal-title":"Immunol Rev"},{"key":"10.1016\/j.vaccine.2025.126989_bb0175","doi-asserted-by":"crossref","first-page":"1360","DOI":"10.3389\/fimmu.2018.01360","article-title":"Activation and regulation of B cell responses by invariant natural killer T cells","volume":"9","author":"Doherty","year":"2018","journal-title":"Front Immunol"},{"key":"10.1016\/j.vaccine.2025.126989_bb0180","doi-asserted-by":"crossref","first-page":"481","DOI":"10.1038\/s41591-022-01705-6","article-title":"Neutralizing antibodies against the SARS-CoV-2 Delta and omicron variants following heterologous CoronaVac plus BNT162b2 booster vaccination","volume":"28","author":"Perez-Then","year":"2022","journal-title":"Nat Med"},{"key":"10.1016\/j.vaccine.2025.126989_bb0185","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2022.975533","article-title":"Neutralization effect of plasma from vaccinated COVID-19 convalescents on SARS-CoV-2 omicron variants","volume":"13","author":"Xie","year":"2022","journal-title":"Front Immunol"},{"key":"10.1016\/j.vaccine.2025.126989_bb0190","doi-asserted-by":"crossref","first-page":"682","DOI":"10.1038\/s41586-022-04399-5","article-title":"Activity of convalescent and vaccine serum against SARS-CoV-2 omicron","volume":"602","author":"Carre\u00f1o","year":"2022","journal-title":"Nature"},{"key":"10.1016\/j.vaccine.2025.126989_bb0195","doi-asserted-by":"crossref","first-page":"358","DOI":"10.1038\/s41591-022-02138-x","article-title":"Infectiousness of SARS-CoV-2 breakthrough infections and reinfections during the omicron wave","volume":"29","author":"Tan","year":"2023","journal-title":"Nat Med"},{"key":"10.1016\/j.vaccine.2025.126989_bb0200","article-title":"Cross-reactive antibody response between SARS-CoV-2 and SARS-CoV infections","author":"Lv","year":"2020","journal-title":"bioRxiv"},{"key":"10.1016\/j.vaccine.2025.126989_bb0205","author":"Organization, W. H"},{"key":"10.1016\/j.vaccine.2025.126989_bb0210","doi-asserted-by":"crossref","first-page":"514","DOI":"10.1038\/nri2802","article-title":"Immunity and immunopathology to viruses: what decides the outcome?","volume":"10","author":"Rouse","year":"2010","journal-title":"Nat Rev Immunol"},{"key":"10.1016\/j.vaccine.2025.126989_bb0215","doi-asserted-by":"crossref","first-page":"e21","DOI":"10.1016\/S2666-5247(21)00275-5","article-title":"T-cell and antibody responses to first BNT162b2 vaccine dose in previously infected and SARS-CoV-2-naive UK health-care workers: a multicentre prospective cohort study","volume":"3","author":"Angyal","year":"2022","journal-title":"Lancet Microbe"},{"key":"10.1016\/j.vaccine.2025.126989_bb0220","article-title":"Negligible impact of SARS-CoV-2 variants on CD4 (+) and CD8 (+) T cell reactivity in COVID-19 exposed donors and vaccinees","author":"Tarke","year":"2021","journal-title":"bioRxiv"},{"key":"10.1016\/j.vaccine.2025.126989_bb0225","doi-asserted-by":"crossref","DOI":"10.1172\/JCI149335","article-title":"SARS-CoV-2 mRNA vaccines induce broad CD4+ T cell responses that recognize SARS-CoV-2 variants and HCoV-NL63","volume":"131","author":"Woldemeskel","year":"2021","journal-title":"J Clin Invest"},{"key":"10.1016\/j.vaccine.2025.126989_bb0230","doi-asserted-by":"crossref","first-page":"1259","DOI":"10.1016\/j.cell.2022.03.022","article-title":"T cell reactivity to the SARS-CoV-2 omicron variant is preserved in most but not all individuals","volume":"185","author":"Naranbhai","year":"2022","journal-title":"Cell"},{"key":"10.1016\/j.vaccine.2025.126989_bb0235","doi-asserted-by":"crossref","first-page":"847","DOI":"10.1016\/j.cell.2022.01.015","article-title":"SARS-CoV-2 vaccination induces immunological T cell memory able to cross-recognize variants from alpha to omicron","volume":"185","author":"Tarke","year":"2022","journal-title":"Cell"},{"key":"10.1016\/j.vaccine.2025.126989_bb0240","doi-asserted-by":"crossref","first-page":"488","DOI":"10.1038\/s41586-022-04460-3","article-title":"T cell responses to SARS-CoV-2 spike cross-recognize omicron","volume":"603","author":"Keeton","year":"2022","journal-title":"Nature"},{"key":"10.1016\/j.vaccine.2025.126989_bb0245","doi-asserted-by":"crossref","first-page":"1154496","DOI":"10.3389\/fimmu.2023.1154496","article-title":"Protection from COVID-19 disease in hamsters vaccinated with subunit SARS-CoV-2 S1 mucosal vaccines adjuvanted with different adjuvants","volume":"14","author":"Sui","year":"2023","journal-title":"Front Immunol"},{"key":"10.1016\/j.vaccine.2025.126989_bb0250","doi-asserted-by":"crossref","first-page":"594","DOI":"10.1038\/s41586-020-2814-7","article-title":"COVID-19 vaccine BNT162b1 elicits human antibody and T(H)1 T cell responses","volume":"586","author":"Sahin","year":"2020","journal-title":"Nature"},{"key":"10.1016\/j.vaccine.2025.126989_bb0255","doi-asserted-by":"crossref","first-page":"457","DOI":"10.1038\/s41586-020-2550-z","article-title":"SARS-CoV-2-specific T cell immunity in cases of COVID-19 and SARS, and uninfected controls","volume":"584","author":"Le Bert","year":"2020","journal-title":"Nature"},{"key":"10.1016\/j.vaccine.2025.126989_bb0260","doi-asserted-by":"crossref","DOI":"10.1016\/j.celrep.2021.108728","article-title":"Early induction of functional SARS-CoV-2-specific T cells associates with rapid viral clearance and mild disease in COVID-19 patients","volume":"34","author":"Tan","year":"2021","journal-title":"Cell Rep"},{"key":"10.1016\/j.vaccine.2025.126989_bb0265","doi-asserted-by":"crossref","first-page":"2133","DOI":"10.1016\/j.immuni.2021.08.001","article-title":"Rapid induction of antigen-specific CD4(+) T cells is associated with coordinated humoral and cellular immunity to SARS-CoV-2 mRNA vaccination","volume":"54","author":"Painter","year":"2021","journal-title":"Immunity"},{"key":"10.1016\/j.vaccine.2025.126989_bb0270","doi-asserted-by":"crossref","first-page":"abm0829","DOI":"10.1126\/science.abm0829","article-title":"mRNA vaccines induce durable immune memory to SARS-CoV-2 and variants of concern","volume":"374","author":"Goel","year":"2021","journal-title":"Science"},{"key":"10.1016\/j.vaccine.2025.126989_bb0275","doi-asserted-by":"crossref","first-page":"682","DOI":"10.1016\/j.medj.2021.04.003","article-title":"Early T cell and binding antibody responses are associated with COVID-19 RNA vaccine efficacy onset","volume":"2","author":"Kalimuddin","year":"2021","journal-title":"Med"},{"key":"10.1016\/j.vaccine.2025.126989_bb0280","doi-asserted-by":"crossref","first-page":"495","DOI":"10.15585\/mmwr.mm7013e3","volume":"70","author":"Thompson","year":"2021","journal-title":"MMWR Morb Mortal Wkly Rep"},{"key":"10.1016\/j.vaccine.2025.126989_bb0285","doi-asserted-by":"crossref","first-page":"eabi8961","DOI":"10.1126\/scitranslmed.abi8961","article-title":"Robust immune responses are observed after one dose of BNT162b2 mRNA vaccine dose in SARS-CoV-2-experienced individuals","volume":"14","author":"Samanovic","year":"2022","journal-title":"Sci Transl Med"},{"key":"10.1016\/j.vaccine.2025.126989_bb0290","doi-asserted-by":"crossref","DOI":"10.1016\/j.ebiom.2022.104294","article-title":"Dynamics of humoral and cellular immune responses after homologous and heterologous SARS-CoV-2 vaccination with ChAdOx1 nCoV-19 and BNT162b2","volume":"85","author":"Vogel","year":"2022","journal-title":"EBioMedicine"},{"key":"10.1016\/j.vaccine.2025.126989_bb0295","doi-asserted-by":"crossref","first-page":"1137","DOI":"10.1038\/s41598-024-51505-w","article-title":"Measurement of IFN-\u03b3 and IL-2 for the assessment of the cellular immunity against SARS-CoV-2","volume":"14","author":"Safont","year":"2024","journal-title":"Sci Rep"},{"key":"10.1016\/j.vaccine.2025.126989_bb0300","article-title":"Kinetics of antibody responses dictate COVID-19 outcome","author":"Lucas","year":"2020","journal-title":"medRxiv"},{"key":"10.1016\/j.vaccine.2025.126989_bb0305","doi-asserted-by":"crossref","first-page":"1508","DOI":"10.1016\/j.cell.2020.10.052","article-title":"Compromised humoral functional evolution tracks with SARS-CoV-2 mortality","volume":"183","author":"Zohar","year":"2020","journal-title":"Cell"},{"key":"10.1016\/j.vaccine.2025.126989_bb0310","doi-asserted-by":"crossref","first-page":"235","DOI":"10.1089\/jamp.2022.0072","article-title":"Aerosol particle size influences the infectious dose and disease severity in a Golden Syrian Hamster model of inhalational COVID-19","volume":"36","author":"Boydston","year":"2023","journal-title":"J Aerosol Med Pulm Drug Deliv"},{"key":"10.1016\/j.vaccine.2025.126989_bb0315","doi-asserted-by":"crossref","first-page":"11369","DOI":"10.1038\/s41598-022-15238-y","article-title":"Protection of hamsters challenged with SARS-CoV-2 after two doses of MVC-COV1901 vaccine followed by a single intranasal booster with nanoemulsion adjuvanted S-2P vaccine","volume":"12","author":"Lin","year":"2022","journal-title":"Sci Rep"},{"key":"10.1016\/j.vaccine.2025.126989_bb0320","article-title":"Immunogenicity and efficacy of recombinant subunit SARS-CoV-2 vaccine candidate in the Syrian hamster model","volume":"37","author":"Shanmugaraj","year":"2023","journal-title":"Biotechnol Rep (Amst)"},{"key":"10.1016\/j.vaccine.2025.126989_bb0325","doi-asserted-by":"crossref","first-page":"6193","DOI":"10.1038\/s41467-024-50133-2","article-title":"Multi-antigen intranasal vaccine protects against challenge with sarbecoviruses and prevents transmission in hamsters","volume":"15","author":"Leekha","year":"2024","journal-title":"Nat Commun"},{"key":"10.1016\/j.vaccine.2025.126989_bb0330","article-title":"Epitope-resolved profiling of the SARS-CoV-2 antibody response identifies cross-reactivity with endemic human coronaviruses","volume":"2","author":"Ladner","year":"2021","journal-title":"Cell Rep Med"},{"key":"10.1016\/j.vaccine.2025.126989_bb0335","doi-asserted-by":"crossref","DOI":"10.1016\/j.celrep.2022.111022","article-title":"COVID-19 vaccination elicits an evolving, cross-reactive antibody response to epitopes conserved with endemic coronavirus spike proteins","volume":"40","author":"Elko","year":"2022","journal-title":"Cell Rep"},{"key":"10.1016\/j.vaccine.2025.126989_bb0340","article-title":"Humoral immune response to SARS-CoV-2 spike protein receptor-binding motif linear epitopes","volume":"12","author":"Monteiro","year":"2024","journal-title":"Vaccines (Basel)"},{"key":"10.1016\/j.vaccine.2025.126989_bb0345","doi-asserted-by":"crossref","DOI":"10.3389\/fmedt.2022.1009451","article-title":"SARS-CoV-2 variants impact RBD conformational dynamics and ACE2 accessibility","volume":"4","author":"Val\u00e9rio","year":"2022","journal-title":"Front Med Technol"},{"key":"10.1016\/j.vaccine.2025.126989_bb0350","doi-asserted-by":"crossref","first-page":"111","DOI":"10.1586\/14760584.1.1.111","article-title":"Montanide ISA 720 and 51: a new generation of water in oil emulsions as adjuvants for human vaccines","volume":"1","author":"Aucouturier","year":"2002","journal-title":"Expert Rev Vaccines"},{"key":"10.1016\/j.vaccine.2025.126989_bb0355","doi-asserted-by":"crossref","first-page":"307","DOI":"10.1186\/s40425-019-0796-5","article-title":"A new synthetic toll-like receptor 1\/2 ligand is an efficient adjuvant for peptide vaccination in a human volunteer","volume":"7","author":"Rammensee","year":"2019","journal-title":"J Immunother Cancer"},{"key":"10.1016\/j.vaccine.2025.126989_bb0360","doi-asserted-by":"crossref","first-page":"10297","DOI":"10.1038\/s41598-024-61025-2","article-title":"Immunoinformatics design of a structural proteins driven multi-epitope candidate vaccine against different SARS-CoV-2 variants based on fynomer","volume":"14","author":"Sarvmeili","year":"2024","journal-title":"Sci Rep"},{"key":"10.1016\/j.vaccine.2025.126989_bb0365","doi-asserted-by":"crossref","DOI":"10.1016\/j.cellsig.2020.109721","article-title":"Drugs targeting various stages of the SARS-CoV-2 life cycle: Exploring promising drugs for the treatment of Covid-19","volume":"74","author":"Poduri","year":"2020","journal-title":"Cell Signal"},{"key":"10.1016\/j.vaccine.2025.126989_bb0370","doi-asserted-by":"crossref","DOI":"10.1002\/jcla.24479","article-title":"Nucleocapsid protein of SARS-CoV-2 is a potential target for developing new generation of vaccine","volume":"36","author":"Feng","year":"2022","journal-title":"J Clin Lab Anal"},{"key":"10.1016\/j.vaccine.2025.126989_bb0375","doi-asserted-by":"crossref","unstructured":"Myburgh, L. Guided design for the development of an evolution-proof influenza vaccine. Manuscript in preparation (2024).","DOI":"10.1016\/j.vaccine.2025.127281"},{"key":"10.1016\/j.vaccine.2025.126989_bb0380","doi-asserted-by":"crossref","first-page":"480","DOI":"10.1007\/BF01863914","article-title":"Beitrag zur kollektiven Behandlung pharmakologischer Reihenversuche","volume":"162","author":"K\u00e4rber","year":"1931","journal-title":"Naunyn Schmiedebergs Arch Exp Pathol Pharmakol"},{"key":"10.1016\/j.vaccine.2025.126989_bb0385","first-page":"227","article-title":"The method of right and wrong cases (constant stimuli) without Gauss\u2019s formulae","volume":"2","author":"Spearman","year":"1908","journal-title":"Br J Psychol"}],"container-title":["Vaccine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0264410X25002865?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0264410X25002865?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,11,4]],"date-time":"2025-11-04T17:43:11Z","timestamp":1762278191000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0264410X25002865"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,4]]},"references-count":77,"alternative-id":["S0264410X25002865"],"URL":"https:\/\/doi.org\/10.1016\/j.vaccine.2025.126989","relation":{},"ISSN":["0264-410X"],"issn-type":[{"value":"0264-410X","type":"print"}],"subject":[],"published":{"date-parts":[[2025,4]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Targeting the early life stages of SARS-CoV-2 using a multi-peptide conjugate vaccine","name":"articletitle","label":"Article Title"},{"value":"Vaccine","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.vaccine.2025.126989","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 The Authors. Published by Elsevier Ltd.","name":"copyright","label":"Copyright"}],"article-number":"126989"}}